The National Osteoporosis Foundation (NOF) sponsored the Sixth International Symposium on Osteoporosis: Current Status & Future Directions held on April 6-10, 2005, in Washington, DC, USA. The program, which attracted over 1300 attendees, was co-chaired by Deborah T Gold, PhD, and Robert Lindsay, MD, PhD. The goal of the meeting was to provide physicians and other healthcare practitioners with the most current and clinically relevant information on the prevention, diagnosis, and treatment of osteoporosis. The symposium was immediately followed by the Bone Densitometry Course and Vertebral Fracture Assessment Course of the International Society for Clinical Densitometry. Bess Dawson-Hughes, MD, NOF President, opened the symposium, followed by keynote speaker John A Eisman, PhD, who discussed global issues in the care of osteoporosis. A selection of plenary addresses of interest is presented here.
Key presentations
Osteoporosis is a common disorder with serious clinical consequences. In the USA, 8 million women and 2.5 million men have osteoporosis, resulting in direct healthcare expenses of $32-47 million per day. The personal costs of osteoporotic fractures, in terms of chronic pain, disability, depression, and loss of independence, are immeasurable. Ageadjusted mortality after an osteoporotic fracture increases two-to threefold.
Despite the vast knowledge that has accumulated about the devastating impact of osteoporosis on individuals and society, it is still underdiagnosed and undertreated. Dr John Eisman provided a comprehensive review of the factors that contribute to the 'under-management' of osteoporosis and the many management challenges we now face in improving osteoporosis care worldwide. From a public health viewpoint, there is much to be done to implement the foundation of all osteoporosis management programs: regular weight-bearing exercise, adequate daily intake of calcium and vitamin D, and avoidance of agents that are toxic to bone, such as cigarette smoking and excess alcohol. General awareness of these lifestyle and nutritional issues is far from optimal, with implementation even more problematic. At the level of healthcare providers, patients at high risk for fracture are often not identified and evaluated. Postmenopausal women with clinical risk factors, such as advanced age, family history of fracture, cigarette smoking, and low body weight, are too often not selected for bone density testing. There is widespread under-reporting of vertebral fractures on x-rays, probably due to a lack of appreciation of their clinical significance and absence of consensus in the medical community for defining vertebral fractures. When fragility fractures of the spine or other skeletal sites are diagnosed in patients over 45-50 years of age, all too often there is no further evaluation and treatment, despite very high risk for future fracture. Healthcare providers are poorly adherent to current guidelines for bone mineral density (BMD) testing and osteoporosis treatment, and patients are poorly adherent to therapy. Studies have repeatedly shown that less than 50% of patients treated for osteoporosis are still taking medication 1 year later. Despite an abundance of evidence that lifestyle changes and appropriate use of pharmacologic agents can cost-effectively reduce the risk of fragility fractures in properly selected patients, there is still a large 'treatment gap'-the difference between those who should be treated and those who are treated. Dr Eisman discussed current barriers to treatment. He suggested that the perceived 'window of treatment' -the time in a patient's life when healthcare providers feel that intervention is appropriate -is far too small. Early postmenopausal women are often thought to be 'too young' for treatment, and elderly women are thought to be 'too old.' Osteoporosis myths were explored, including sentiment by some that osteoporosis is an inevitable consequence of aging that cannot or should not be treated. Other physician barriers to care include the cost of treatment, the time and cost of diagnosis, lack of clarity regarding which healthcare provider is responsible for osteoporosis care, polypharmacy concerns, poor understanding of clinical risk factors and lack of appreciation of the long-term consequences of fractures. Patients may not be aware of the level of risk or the personal consequences of fractures. They may have concerns about the effectiveness, safety and cost of drug therapy, and may have cultural barriers to effective management. Concepts for improving osteoporosis management include community awareness and education campaigns, healthcare system approaches for 'capturing' patients for post-fracture care, and further research to develop drugs that are less expensive, safer, and with more convenient dosing.
An overview of the Surgeon General's 'Report on Bone Health and Osteoporosis'
was presented by Drs Joan McGowan, Senior Scientific Editor, and Lawrence Raisz, Scientific Editor. Surgeon General Richard Carmona, MD, also attended the meeting to discuss the report with leaders of medical organizations representing over 60,000 physicians worldwide. Dr Carmona expressed a strong desire to work with the private sector in disseminating the information in the report to healthcare providers and the lay public. The decision to produce the report was made because of the large body of evidence showing that lifestyle and medical intervention can improve skeletal health, in a setting where much of this is not being implemented. It is intended to be 'a driver of change' -a call to action to plug the treatment gap. The report includes a summary of current knowledge in bone biology, the impact of osteoporosis on society and individuals, and the state-of-the-art for prevention, diagnosis and treatment of osteoporosis. It was repeatedly emphasized by these speakers and others that a fracture in an adult over 45-50 years is a sentinel event that should trigger further investigation and consideration of aggressive treatment to prevent future fractures. Data were presented showing that only 18% of Medicare patients with fragility fractures had a bone density test or received treatment for osteoporosis in 2003. The Centers for Medicare & Medicaid Services (CMS) is addressing this deficiency by supporting the current National Committee for Quality Assurance (NCQA) Health Plan Employer Data and Information Set (HEDIS) measure of the percentage of women age 67 years and older who are diagnosed with a fracture and then receive either a BMD test or prescription treatment for osteoporosis with 6 months of the date of the fracture. Dr Raisz offered advice on how to improve bone health: council the young on healthy lifestyle, measure BMD in those at risk for fractures, treat those who are high risk, follow patients carefully to assure adherence to therapy, and use the Surgeon's Generals Report as a guide for care.
Dr Bess Dawson-Hughes reviewed the nutritional requirements for elderly patients with osteoporosis. Calcium and vitamin deficiency are common at all ages, but especially so in the elderly. Pharmacologic agents to prevent or treat osteoporosis may be less effective or ineffective when nutritional deficiencies are present. If dietary calcium is insufficient, then calcium supplements should be used. The NOF recommends a daily intake of at least 1200 mg elemental calcium with diet plus supplements in all women over age 50 years. Recent research has improved our understanding of the role of vitamin D in skeletal and nonskeletal health. Historically, the recommended daily dose of vitamin D was set at 400 international units (IU) (about the amount contained in a teaspoon of cod liver oil) because this dose is usually sufficient to prevent rickets in children and osteomalacia in adults. It was subsequently found that low vitamin D levels are associated with the development of osteoporosis and nonskeletal risk factors for fracture, such as loss of muscle strength, poor balance, and falling. Vitamin D levels for optimal skeletal and muscular health are considerably higher than levels needed to prevent rickets and osteomalacia. Many experts now recommend a target range of 30-57 ng/ml for serum 25hydroxyvitamin D, which may require a daily oral intake of vitamin D of 1000 IU or more. Since the food sources of vitamin D are few, and exposure to the sun is often limited in the elderly, vitamin D supplements are often necessary to achieve this. Recent studies suggest that vitamin D3 (cholecalciferol) may be more potent than vitamin D2 (ergocalciferol). It is the blood level of 25-hydroxyvitamin D, and not 1,25-dihydroxyvitamin D, that best reflects vitamin D stores. Assay variability should be considered when ordering any vitamin D assay, since a chemiluminescent assay was recently shown to 'under-report' D 2 . Assay type may be a clinically important issue when monitoring levels in a patient being replaced with the D 2.
The evaluation of patients with osteoporosis was discussed by Dr Marjorie Luckey. Questions faced by all clinicians caring for osteoporosis patients include: Who should be evaluated for factors contributing to osteoporosis? What tests should be done? How often are the tests abnormal? Dr Luckey presented evidence showing that factors other than estrogen deficiency and aging are often found by doing a few cost-effective tests, and that clinicians should have a high index of suspicion in all patients with osteoporosis. In one study, a testing strategy of measuring 24-h urinary calcium, serum calcium and serum parathyroid level in all women, and serum thyroid-stimulating hormone (TSH) in those on thyroid replacement, effectively revealed most significant previously undiagnosed disorders. She also suggested a few simple office tests to evaluate patients for undiagnosed vertebral compression fractures, such as an accurate height measurement with a stadiometer (a loss of >1.5-2.0 inches may be significant), inability to place the occiput against the wall when standing straight with back to wall, and distance between bottom ribs and pelvic brim of less than two fingerbreadths.
Current and emerging treatments for osteoporosis were presented by many speakers. It was proposed by Dr Lawrence Riggs that a new nomenclature for classifying drugs used to treat osteoporosis. He suggests that the term 'anticatabolic' replace 'antiresorptive' in describing drugs such as the bisphosphonates, selective estrogen receptor modulators, salmon calcitonin and estrogen, in recognition that these drugs increase bone strength by decreasing bone remodeling, not just resorption. The other class of drugs is 'anabolic' -those that increase bone strength by an overall increase in bone remodeling with formation greater than resorption. The only currently approved drug in this class is teriparatide. Some drugs, such as strontium ranelate, appear to have both anticatabolic and anabolic properties, and are difficult to place in one class or the other. Trends in osteoporosis therapy are toward less frequent dosing and parenteral dosing, both of which may help to improve patient adherence to Update on Osteoporosis -CONFERENCE SCENE therapy while maintaining or improving the efficacy and safety of currently available drugs. Nonskeletal benefits of drugs are receiving greater attention with data showing that vitamin D therapy may improve balance and reduce fall risk, and evidence that some SERMs may decrease the risk of invasive estrogen receptor positive breast cancer. Novel new drugs in development are designed to capitalize on advancements in the molecular biology in such ways as targeting pathways regulating osteoclast differentiation and function or inhibiting cathepsin-K.
Dr Ethyl Siris, President-Elect of the NOF, presented data from the National Osteoporosis Risk Assessment (NORA) study. Over 200,000 American women not known to have osteoporosis were evaluated with various types of peripheral BMD tests and followed for 1 year for clinical fractures. It was shown that the lower the bone density, regardless of technology used and skeletal site measured, the greater the risk of fracture. It was also demonstrated that most women with fractures had a bone density that was slightly low but not 'osteoporosis' (Tscore ≤-2.5 at a peripheral site). Although fracture probability was less in these women, there were so many more of them that the absolute number of fractures was greater. This is analogous to a more familiar scenario for many clinicians, where most patients with acute myocardial infarction have slightly high, but not necessarily extremely high serum cholesterol. Physicians may be familiar with practice guidelines suggesting pharmacologic therapy for women with Tscores of less than -2.0 or -2.5, but the bigger challenge in clinical practice is to identify those with higher T-scores who are also at high risk of fracture and should be treated.
One approach to improve the selection of patients for cost-effective pharmacologic intervention is through assessment of fracture probability. Dr John Kanis, who is directing a program of the World Health Organization (WHO) to develop a methodology for predicting fracture risk, showed progress made to date. The WHO Collaborating Centre for Metabolic Bone Diseases is collaborating with other researchers to perform a 'mega-analysis' of at least 12 large prospective observational trials in approximately 60,000 women and men. The intent is to combine BMD with clinical risk factors to calculate a fracture probability for individual patients. These risk factors must be ones that are independent of BMD, easily obtainable in clinical practice, amendable to treatment with the agents under consideration, and validated in women and men with different ethnicities in different world regions. Risk factors to be used have not yet been determined, but those under consideration include age, previous fracture, glucocorticoid use, parental history of hip fracture, cigarette smoking, excess alcohol intake, and rheumatoid arthritis. By means of a cost-utility analysis that is consistent with the economic resources, healthcare priorities, and culture of the country involved, a country-specific cost-effective intervention threshold can be established.
Summary
The Sixth International Symposium on Osteoporosis brought together many of the world leaders in the fields of bone biology, osteoporosis treatment, and assessment of skeletal strength. A wide range of topics was addressed, from disturbing data on the 'treatment gap' for osteoporosis care, to optimism that public health programs combined with hands-on efforts to educate and treat individual patients will reduce the worldwide burden of osteoporotic fractures. Vigorous promotion of healthy lifestyles, evaluation of patients at risk for fractures and appropriate use of currently available medications should be goals of all stakeholders in our healthcare systems. New methodologies to express fracture risk and promising new medications for the treatment of osteoporosis are being developed.
Future perspective
Public health initiatives to improve the awareness of healthcare providers and the public on skeletal heath issues are likely to expand in the near future. Bone density testing will continue to be the best clinical tool to evaluate patients for fracture risk in the absence of a fragility fracture. New technologies to evaluate other bone properties that are associated with bone strength will be developed. More office-based methods to evaluate patients for fracture risk will emerge, and new medications with novel mechanisms of action and improved dosing systems will become available.
To learn more about osteoporosis and bone density testing: More information on osteoporosis for patients and healthcare providers is on the website of the National Osteoporosis Foundation at www.nof.org.
To learn more about bone density testing, scheduled CME courses in bone densitometry, and the Official Positions of the International Society for Clinical Densitometry, visit www.iscd.org.
The Surgeon General's Report on Bone Health and Osteoporosis can be downloaded as a PDF file or ordered as a print copy at no charge. To obtain the report, go to www.surgeongeneral.gov or call 1-866-718-BONE (2663) .
Highlights
• Osteoporosis is underdiagnosed and -treated, even in those with previous fragility fracture, who are at very high risk for future fracture.
• Physician adherence to guidelines for bone density testing and treatment of osteoporosis is poor.
• Patient adherence to therapy for osteoporosis is poor-typically less than 50% at 1 year.
• Although the risk of fragility fracture is highest in patients with osteoporosis (T-score ≤-2.5), most fractures occur in women who have a T-score higher than -2.5, because there are so many more of these women.
• Most patients have an insufficient daily intake of calcium and vitamin D for optimal skeletal health.
• Methodologies are under development to combine bone density testing with assessment of validated clinical risk factors for fracture to estimate the probability of fragility fracture and potentially establish intervention thresholds.
